Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Recombinant human growth hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    72 result(s) found for: Recombinant human growth hormone. Displaying page 4 of 4.
    « Previous 1  2  3  4 
    EudraCT Number: 2006-006550-96 Sponsor Protocol Number: TN-07 Start Date*: 2007-03-23
    Sponsor Name:NIDDK TYPE 1 DIABETES TRIALNET
    Full Title: Oral insulin for prevention of diabetes in relatives at risk for type 1 diabetes mellitus
    Medical condition: prevention of type 1 diabetes mellitus in subjects at risk for T1DM
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045228 Type I diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) FI (Completed) DE (Completed) GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001518-15 Sponsor Protocol Number: KFE001 Start Date*: 2004-09-09
    Sponsor Name:Hvidovre Hospital
    Full Title: Effekten af lavdosis væksthormonbehandling hos HIV positive patienter i højaktiv antiretroviral behandling (HAART)
    Medical condition: HIV infection
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003681-40 Sponsor Protocol Number: WO42633 Start Date*: 2021-03-01
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST C...
    Medical condition: Early human epidermal growth factor receptor 2 (HER2) positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000525-25 Sponsor Protocol Number: 61186372NSC3004 Start Date*: 2022-09-05
    Sponsor Name:JANSSEN CILAG INTERNATIONAL NV
    Full Title: A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous on Body Deliv...
    Medical condition: EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003391-37 Sponsor Protocol Number: Scil-MD05-C01 Start Date*: 2005-12-05
    Sponsor Name:Scil Technology GmbH
    Full Title: Pilot Study on Safety and explorative Efficacy of MD05 in Comparison with the Medical Device Beta-TCP Mixed with Autogenous Bone Material in Patients Undergoing Two-Stage Unilateral Maxillary Sinus...
    Medical condition: Requirement of two-stage unilateral maxillary sinus floor augmentation in case of insufficient bone height in the area of the posterior maxilla, prior to insertion of dental implants.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10061257 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005883-25 Sponsor Protocol Number: Scil-MD05-C02 Start Date*: 2007-04-25
    Sponsor Name:Scil Technology GmbH
    Full Title: Pilot Study on Safety and Explorative Efficacy of MD05 in Comparison with Open Flap Debridement in Patients Undergoing Periodontal Surgery to Treat Deep Intrabony Defects
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    8.1 10034536 Periodontal disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004000-33 Sponsor Protocol Number: INZ701-201 Start Date*: 2021-06-10
    Sponsor Name:Inozyme Pharma, Inc.
    Full Title: A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period i...
    Medical condition: Treatment of patients with ABCC6 Deficiency Manifesting as Pseudoxanthoma elasticum (PXE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10037150 Pseudoxanthoma elasticum PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002682-19 Sponsor Protocol Number: PHI113633 Start Date*: 2013-12-20
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A Phase 2B, randomized, blinded, dose-ranging, active-controlled, parallel-group, multi-center study to evaluate the dose response relationship of GSK1278863 over the first 4 weeks of treatment and...
    Medical condition: Anemia associated with chronic kidney disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) CZ (Completed) GB (Completed) DK (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005441-32 Sponsor Protocol Number: DIAGNODE-B Start Date*: 2021-12-28
    Sponsor Name:Linköping University
    Full Title: DIAGNODE-B, A Phase I/II Open Label Pilot Study to evaluate the safety and feasibility of an additional intralymphatic booster administration of GAD-alum (Diamyd®) in individuals with Type 1 diabetes
    Medical condition: Type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004050-29 Sponsor Protocol Number: PHI116581 Start Date*: 2013-01-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A four-week Phase IIa, randomized, double-blind, placebocontrolled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in subjects with anemia as...
    Medical condition: Anemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004049-34 Sponsor Protocol Number: PHI116582 Start Date*: 2013-01-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from a stable dose of recombina...
    Medical condition: Anaemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-002731-32 Sponsor Protocol Number: D/P3/21/7 Start Date*: Information not available in EudraCT
    Sponsor Name:Diamyd Medical AB
    Full Title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults with...
    Medical condition: Type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10045228 Type I diabetes mellitus LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing) DE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) EE (Trial now transitioned) HU (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 28 03:43:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA